THE STRATEGIC IMPORTANCE OF IN-HOUSE PRODUCT DEVELOPMENT IN MAXILLOFACIAL PRACTICE

The article explores the strategic importance of in-house product development in private maxillofacial practice to integrate clinical innovation with business sustainability. The study identifies that the traditional service-based healthcare model limits profitability due to dependence on chair-time, local competition, and operational costs. Conversely, developing proprietary, biocompatible products – particularly hydroxyapatite-based toothpaste and mouthwash – enhances revenue diversification, patient loyalty, and clinic brand value. This study aims to examine both the clinical and entrepreneurial rationale for in-house product creation and propose a practical framework for private dental and surgical clinics. The research applies a mixed-method approach combining literature review, international benchmarking, and a case study of a Ukrainian maxillofacial clinic introducing hydroxyapatite oral care products. Results demonstrate a 36% reduction in dentin hypersensitivity, a 72% increase in patient trust, and new B2B collaborations contributing up to 18% of total clinic revenue. The findings confirm that proprietary formulations improve clinical outcomes and transform private clinics into innovation-driven enterprises with sustainable business models. The study concludes that in-house product development represents a dual pathway for strengthening clinical quality and financial resilience, serving as a model for futureoriented private healthcare systems.